Clinical Trials Logo

Clinical Trial Summary

Bevacizumab is an anti vascular endothelial growth factor(anti-VEGF) substance that is known to reduce neovascularization and fibrovascular proliferation in inflammatory conditions, including post-operative inflammation. It has shown efficacy in numerous ocular conditions(off-label), that includes Age related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma and corneal neovascularization. It is being explored as an option for preventing recurrence of pterygium and as an adjunct to improving outcomes of trabeculectomy. There is a debate as to the mode and duration of bevacizumab administration for trabeculectomy. This study aims to compare a single subconjunctival dose of bevacizumab with topical therapy over one month in terms of outcomes of trabeculectomy surgery, non-progression of field loss and stable intraocular pressure(IOP) control.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01425112
Study type Interventional
Source Sudhalkar Eye Hospital
Contact
Status Completed
Phase N/A
Start date December 2007
Completion date June 2011

See also
  Status Clinical Trial Phase
Recruiting NCT04581122 - A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components N/A
Recruiting NCT03509779 - Pronostic and Predictive Value of EMT in Localized Lung Cancer
Recruiting NCT06174324 - Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation
Recruiting NCT04422223 - Prospective Cohort Study of Disease and Outcomes in Cirrhosis
Active, not recruiting NCT04682457 - Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.
Recruiting NCT03121768 - A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) N/A
Completed NCT01980212 - Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
Recruiting NCT05983003 - Research on Identifying and Treatment Prognosis of Chronic Rhinosinusitis Based on Image and Sequencing Data
Recruiting NCT05942456 - Soluble B7-H3 as a Biomarker for Osteosarcoma
Not yet recruiting NCT05361772 - Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial N/A
Recruiting NCT03582527 - PD-L1 Expression in Advanced Osteosarcoma
Completed NCT01651078 - Laser Ablation After Stereotactic Radiosurgery
Active, not recruiting NCT02761070 - Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Phase 3
Not yet recruiting NCT05791630 - The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) N/A
Enrolling by invitation NCT03451929 - Kidney Function and Cardiovascular Events: Cohort Study in General Population N/A
Recruiting NCT05153330 - Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL Phase 1
Not yet recruiting NCT05184829 - A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1 N/A
Recruiting NCT04905056 - A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules Phase 2
Recruiting NCT04525833 - Liver Disease and Other Systemic Diseases
Completed NCT06235853 - Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer